PharmacoEconomics & Outcomes News 804, p15 - 2 Jun 2018 GRADE criteria may improve economic evaluations Use of Grading of Recommendations Assessment, Development and Evaluation (GRADE) group criteria may improve the quality of clinical evidence used in cost-effectiveness models, say authors of a Janssen- Cilag affiliated study published in PharmacoEconomics. GRADE criteria were applied to clinical evidence used in 72 modelling studies eavluating interventions for asthma, chronic obstructive pulmonary disease, depression or type 2 diabetes mellitus published between 2001 and 2015, to investigate whether clinical data in cost-effectiveness modelling were appropriate. The criteria were applied to: selection of clinical data (publication bias); imprecision, indirectness or inconsistency (heterogeneity); and study limitations (risk of bias). Despite three quarters of modelling studies being based on data from randomised controlled trials, over 60% were based on clinical data with a high or unclear risk of bias, a risk of publication bias was found in over 80% of studies, and evidence was based on indirect clinical evidence in 30% of studies. In addition, study limitations were inadequately described in over one third of the studies. However, study results showed inconsistency or imprecision in less than 10% of clinical studies. "Despite the fact that the majority of economic evaluations are based on precise and consistent randomized controlled trials, their results are often affected by limitations arising from methodological shortcomings in the underlying data on clinical efficacy. Modelers and assessors should be more aware of aspects surrounding the quality of clinical evidence as considered by the Grading of Recommendations Assessment, Development and Evaluation group," said the authors. Mensch A, et al. Applying GRADE Criteria to Clinical Inputs to Cost- Effectiveness Modeling Studies. PharmacoEconomics : 28 May 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0651-4 803324249 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804
PharmacoEconomics & Outcomes News – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera